Robert F. Murphy | Academic Influence

Robert F. Murphy 's AcademicInfluence.com Rankings

Robert F. Murphy

Computer Science

#3673

World Rank

#3861

Historical Rank

#1352

USA Rank

Database

#7699

World Rank

#8001

Historical Rank

#962

USA Rank

computer-science Degrees

Robert F. Murphy

Biology

#3512

World Rank

#5364

Historical Rank

#1415

USA Rank

Computational Biology

#85

World Rank

#85

Historical Rank

#26

USA Rank

Bioinformatics

#217

World Rank

#219

Historical Rank

#28

USA Rank

biology Degrees

Download Badge

Computer Science
Biology

Robert F. Murphy 's Degrees

Bachelors Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Robert F. Murphy Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Robert F. Murphy is Ray and Stephanie Lane Professor of Computational Biology Emeritus and Director of the M.S. Program in Automated Science at Carnegie Mellon University. Prior to his retirement in May 2021, he was the Ray and Stephanie Lane Professor of Computational Biology as well as Professor of Biological Sciences, Biomedical Engineering, and Machine Learning. He was founding Director of the Center for Bioimage Informatics at Carnegie Mellon and founded the Joint CMU-Pitt Ph.D. Program in Computational Biology. He also founded the Computational Biology Department at Carnegie Mellon University and served as its head from 2009 to 2020.

(See a Problem?)

Robert F. Murphy 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hybridization of synthetic oligodeoxyribonucleotides to ΦX 174 DNA: the effect of single base pair mismatch (1979) (607)
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. (2009) (228)
Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. (1992) (152)
A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. (1991) (127)
Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. (2010) (116)
Flow cytometric DNA analysis of Neuroblastoma and Ganglioneuroma. A 10‐year retrospective study (1988) (112)
Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. (1997) (110)
The pharmacokinetics of zidovudine administered by continuous infusion in children. (1989) (101)
Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. (1998) (97)
Nutlin-3 Protects Kidney Cells during Cisplatin Therapy by Suppressing Bax/Bak Activation* (2007) (95)
Pharmacokinetics of subcutaneous methotrexate. (1988) (86)
Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. (1998) (80)
Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. (1995) (78)
Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates (2010) (75)
The effect of methotrexate on the bioavailability of oral 6‐mercaptopurine (1987) (74)
Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. (1989) (71)
Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. (1993) (70)
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. (1997) (64)
Variability in the oral bioavailability of all-trans-retinoic acid. (1993) (58)
Carboxypeptidase‐G2 rescue in a patient with high dose methotrexate‐induced nephrotoxicity (1995) (57)
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. (2005) (54)
Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. (1992) (54)
Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. (2001) (51)
Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. (1994) (50)
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer (2011) (47)
Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. (1995) (45)
Growth inhibition of 3T3 fibroblasts by lysosomotropic amines: Correlation with effects on intravesicular pH but not vacuolation (1986) (41)
Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. (1995) (41)
Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration (2000) (40)
Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study. (1991) (40)
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer (2016) (39)
Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates (2001) (38)
Flow cytometric DNA analysis of adrenocortical tumors in children (1987) (37)
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations. (1992) (37)
Dose-dependent pharmacokinetics of all-trans-retinoic acid. (1992) (36)
Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia. (1986) (31)
Stability of 5-fluorouracil in whole blood and plasma. (1987) (29)
Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101 (2004) (26)
Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study (2001) (25)
Flow cytometry dna ploidy analysis and catecholamine secretion profiles in neuroblastoma (1990) (22)
Internalization and acidification of insulin by activated human lymphocytes (1984) (22)
Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? (1989) (22)
Pharmacokinetics of 9-cis-retinoic acid in the rhesus monkey. (1995) (21)
A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. (2001) (20)
A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma. (1993) (20)
Relative quantity of cerebrospinal fluid herpes simplex virus DNA in adult cases of encephalitis and meningitis. (2009) (18)
Bioavailability of low‐dose vs high‐dose 6‐mercaptopurine (1988) (18)
Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates. (1990) (18)
Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors (2015) (16)
Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin (2012) (15)
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion (2000) (14)
Pediatric phase I trial design using maximum target inhibition as the primary endpoint. (2010) (14)
Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome (1988) (13)
Desulfuration of 6-mercaptopurine. The basis for the paradoxical cytotoxicity of thiopurines in cultured human leukemic cells. (1993) (9)
Influence on antiproliferative activity of structural modification and conjugation of gonadotropin‐releasing hormone (GnRH) analogues (2000) (9)
Model for concomitant microdialysis sampling of the pons and cerebral cortex in rhesus macaques (Macaca mulatta). (2013) (9)
Pharmacokinetics of the Protease Inhibitor KNI-272 in Plasma and Cerebrospinal Fluid in Nonhuman Primates after Intravenous Dosing and in Human Immunodeficiency Virus-Infected Children after Intravenous and Oral Dosing (1998) (5)
A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. (1997) (4)
Sequence specific effects on DNA and cell damage with the PARP inhibitor olaparib (AZD2281) and carboplatin. (2011) (3)
Absence of Na + , K +-ATPase Regulation of Endosomal Acidification in K 562 Erythroleukemia Cells (2001) (3)
Accumulation of novel transplatinum complexes in cisplatin and oxaliplatin resistant cell lines overcomes resistance (2005) (3)
Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas (1990) (3)
The influence of route of administration on the hepatic uptake of methotrexate. (1986) (2)
Plasma and cerebrospinal fluid pharmacokinetics of doxil after intravenous administration in adults with primary CNS lymphoma. (2017) (1)
High-resolution kinetics of transferrin acidification (1)
Intrathecal 5-fluorouracil in the rhesus monkey (2004) (1)
Pediatric phase I trial design using a pharmacodynamic marker as the primary endpoint (2008) (0)
Pharmacokinetics and Metabolism of CyclopentenylCytosine in Nonhuman Primates (1990) (0)
Author response: Transient protein accumulation at the center of the T cell antigen-presenting cell interface drives efficient IL-2 secretion (2019) (0)
Adenocarcinoma-( Phosphonacetyl )-l-aspartate in Metastatic Gastrointestinal N Calcium Leucovorin in Combination with A Phase I Study of Continuous Infusion 5-Fluorouracil plus Updated (2006) (0)
92. Capacity-limited metabolism of all-trans-retinoic add and the time course of enzyme induction of the non-human primate (1992) (0)
169. Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients and pharmacokinetic evaluation in the nonhuman primate (1992) (0)
Phase I C linical T rial o f A litretinoin a nd T amoxifen i n Breast C ancer P atients: T oxicity, P harmacokinetic, a nd Biomarker E valuations (2001) (0)
Pharmacokinetics of 9-cÂ¿s-RetinoicAcid in the Rhesus Monkey (2006) (0)
Abstract 3599: The plasma and cerebrospinal fluid pharmacokinetics of satraplatin after intravenous administration in non-human primates (2010) (0)
Phase I trial and pharmacokinetic (PK) study of satraplatin in children and young adults with refractory solid tumors including brain tumors. (2013) (0)
Abstract 3374: Effect of bevacizumab and dexamethasone on plasma ultrafiltrate (UF) and cerebrospinal fluid (CSF) pharmacokinetics (PKs) of carboplatin in a non-human primate (NHP) model.: (2013) (0)
Pharmacokinetic rationale fortheinteraction of 5-fluorouracil andmisonidazole inhumans (1983) (0)

This paper list is powered by the following services:

Other Resources About Robert F. Murphy

en.wikipedia.org

What Schools Are Affiliated With Robert F. Murphy ?

Robert F. Murphy is affiliated with the following schools:

Image Attributions

Image Source for Robert F. Murphy